Related Experiment Video

Updated: Jul 5, 2026

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells
07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

Rosiglitazone attenuates insulin-like growth factor 1 receptor survival signaling in PC-3 cells

Efstathia Papageorgiou1, Nea Pitulis, Menelaos Manoussakis

  • 1Department of Experimental Physiology, National and Kapodistrian University of Athens, Goudi-Athens, Greece.

Molecular Medicine (Cambridge, Mass.)
|May 14, 2008
PubMed

Insights

PPARgamma ligands enhance chemotherapy effects in prostate cancer cells. Rosiglitazone specifically promotes apoptosis and blocks IGF-1 survival signals, offering potential for advanced cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Peroxisome proliferator-activated receptor gamma (PPARgamma) is overexpressed in prostate cancer.
  • PPARgamma ligands induce apoptosis and cell cycle arrest in prostate cancer cells.
  • Insulin-like growth factor 1 (IGF-1) promotes survival in prostate cancer cells, inhibiting chemotherapy-induced apoptosis.

Purpose of the Study:

  • To investigate the efficacy of PPARgamma ligands (15dPGJ2 and rosiglitazone) in enhancing adriamycin-induced cytotoxicity in PC-3 prostate cancer cells.
  • To determine if rosiglitazone can overcome IGF-1-mediated survival effects in adriamycin-treated PC-3 cells.
  • To explore the molecular mechanisms underlying rosiglitazone's effects on IGF-1 receptor (IGF-1R) signaling.

Main Methods:

  • Treatment of PC-3 cells with adriamycin, 15dPGJ2, and rosiglitazone.
  • Assessment of cell viability (cytostasis) and apoptosis.
  • Analysis of IGF-1R signaling pathways, including ERK1/2 and AKT phosphorylation.

Main Results:

  • Both PPARgamma ligands increased adriamycin-induced cytostasis.
  • Only rosiglitazone significantly enhanced adriamycin-induced apoptosis.
  • Rosiglitazone attenuated IGF-1R-mediated survival signaling by inhibiting ERK1/2 and AKT phosphorylation via nongenomic action.

Conclusions:

  • Rosiglitazone demonstrates potential in overcoming chemotherapy resistance in prostate cancer.
  • The inhibition of IGF-1R signaling by rosiglitazone offers a novel therapeutic strategy for advanced prostate cancer, particularly in bone metastasis.
  • These findings suggest clinical implications for managing androgen ablation-refractory and chemotherapy-resistant prostate cancer with bone metastasis.

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...